US4208398A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Technetium-labeled complexes, production and use thereof
Assignee: Hoffmann La Roche Inc
•
Filing: 1975-04-21
•
Granted: 1980-06-17
•
Expires: 1995-04-21
Abstract
Abstract Novel chemical complexes containing a radioactive technetium isotope are kidney specific when the complexing agents are certain ionic, water-soluble mercaptans. The complexes can be made by reducing pertechnetate ion and reacting the reduced technetium species with the mercaptan. The complexes are normally used in a biologically sterile, substantially isotonic aqueous medium, for diagnostic purposes.
Inventors
- 👤 David O. Kubiatowicz
- 👤 Theodore F. Bolles
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 14:00
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0491; A61K51/0402; A61K2123/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
26 words
A complex of Tc-99m with a compound of the group consisting of dimercaptosuccinic acid, mercaptosuccinic acid, mercaptoacetic acid, mercaptopropionic acid, 3-mercaptopropylsulfonic acid, thioglucose or thiolactic acid.
Claim 2
Dependent Claim
26 words
A complex of Tc-99m with a compound of the group consisting of dimercaptosuccinic acid, mercaptosuccinic acid, mercaptoacetic acid, mercaptopropionic acid, 3-mercaptopropylsulfonic acid, thioglucose or thiolactic acid.
Claim 3
Dependent Claim
25 words
A complex according to claim 1, in which the complex contains from about 1 to 100 millicuries of Tc-99m for each milligram of complexing agent.
Claim 4
Dependent Claim
19 words
A composition comprising an isotonic solution of complexing agent according to claim 1 in a pharmaceutically acceptable parenteral diluent.
Claim 5
Dependent Claim
16 words
Composition according to claim 3, in which the parenteral diluent is sterile aqueous isotonic saline solution.
Claim 6
Dependent Claim
14 words
A complex according to claim 1, in which the complexing agent is dimercaptosuccinic acid.
Claim 7
Dependent Claim
13 words
A complex according to claim 1, in which the complexing agent is thioglucose.
Claim 8
Dependent Claim
14 words
A complex according to claim 1, in which the complexing agent is mercaptoacetic acid.
Claim 9
Dependent Claim
14 words
A complex according to claim 1, in which the complexing agent is 3-mercaptopropanoic acid.
Claim 10
Dependent Claim
35 words
A radiopharmaceutical complex of technetium-99m with a complexing agent selected from the group consisting of mercaptoacetic acid, dimercaptosuccinic acid, mercaptosuccinic acid and mercaptopropionic acid, said complex prepared in the presence of stannous chloride reducing agent.
Claim 11
Dependent Claim
35 words
A radiopharmaceutical complex of technetium-99m with a complexing agent selected from the group consisting of mercaptoacetic acid, dimercaptosuccinic acid, mercaptosuccinic acid and mercaptopropionic acid, said complex prepared in the presence of stannous chloride reducing agent.
Claim 12
Dependent Claim
12 words
The radiopharmaceutical complex of claim 9 wherein said agent is dimercaptosuccinic acid.
Claim 13
Dependent Claim
37 words
A radiopharmaceutical complex of technetium-99m with a complexing agent selected from the group consisting of mercaptoacetic acid, dimercaptosuccinic acid, mercaptosuccinic acid and mercaptopropionic acid, said complex prepared in the presence of a pharmaceutically-acceptable reducing agent for pertechnetate.
Claim 14
Dependent Claim
37 words
A radiopharmaceutical complex of technetium-99m with a complexing agent selected from the group consisting of mercaptoacetic acid, dimercaptosuccinic acid, mercaptosuccinic acid and mercaptopropionic acid, said complex prepared in the presence of a pharmaceutically-acceptable reducing agent for pertechnetate.
Claim 15
Dependent Claim
31 words
A radiopharmaceutical complex of reduced technetium-99m with a complexing agent selected from the group consisting of mercaptoacetic acid, dimercaptosuccinic acid and mercaptopropionic acid, wherein the technetium-99m is reduced by stannous chloride.
Claim 16
Dependent Claim
31 words
A radiopharmaceutical complex of reduced technetium-99m with a complexing agent selected from the group consisting of mercaptoacetic acid, dimercaptosuccinic acid and mercaptopropionic acid, wherein the technetium-99m is reduced by stannous chloride.
Claim 17
Dependent Claim
12 words
The radiopharmaceutical complex of claim 12 wherein said agent is dimercaptosuccinic acid.
References Cited (Backward Citations)
US3873680A
Cited
US3928552A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-06-17 | 1983-12-17 | 1984-06-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-06-17 | 1987-12-17 | 1988-06-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-06-17 | 1991-12-17 | 1992-06-17 | $7700.00 | Window Closed / Lapsed |